Andrea Wartenberg-Demand
Overview
Explore the profile of Andrea Wartenberg-Demand including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
220
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singer M, Torres A, Heinz C, Weissmuller S, Staus A, Kistner S, et al.
Crit Care
. 2023 Nov;
27(1):436.
PMID: 37946226
Background: The phase II CIGMA trial performed in 160 patients with severe community-acquired pneumonia (sCAP) found treatment with trimodulin (human polyvalent immunoglobulin [Ig]: ~ 23% IgM, ~ 21% IgA, ~ ...
2.
Devlieger R, Buxmann H, Nigro G, Enders M, Juckstock J, Siklos P, et al.
Fetal Diagn Ther
. 2021 Sep;
48(8):611-623.
PMID: 34569538
Introduction: Nonrandomized studies support the potential of cytomegalovirus hyperimmunoglobulin (CMV-HyperIg) in preventing maternofetal CMV transmission, but prospective interventional studies show equivocal results. We pre-sent a prospective phase-III international randomized open-label...
3.
Kelly K, Ailawadhi S, Siegel D, Heffner L, Somlo G, Jagannath S, et al.
Lancet Haematol
. 2021 Sep;
8(11):e794-e807.
PMID: 34529955
Background: Indatuximab ravtansine (BT062) is an antibody-drug conjugate that binds to CD138 and synergistically enhances the antitumor activity of lenalidomide in preclinical models of multiple myeloma. This phase 1/2a study...
4.
Schmidt C, Weissmuller S, Bohlander F, Germer M, Konig M, Staus A, et al.
Biomedicines
. 2021 Aug;
9(7).
PMID: 34356880
Activation of the complement system is important for efficient clearance of a wide variety of pathogens via opsonophagocytosis, or by direct lysis via complement-dependent cytotoxicity (CDC). However, in severe infections...
5.
Schmidt J, Wartenberg-Demand A, Forstmeier S
Trials
. 2020 Oct;
21(1):857.
PMID: 33059730
Background: Equine-assisted therapy is more often practiced with children and adolescents than with the elderly, although individuals in the second half of life could also profit from it. This group,...
6.
Jagannath S, Heffner Jr L, Ailawadhi S, Munshi N, Zimmerman T, Rosenblatt J, et al.
Clin Lymphoma Myeloma Leuk
. 2019 Apr;
19(6):372-380.
PMID: 30930134
Background: Indatuximab ravtansine (BT062) is an antibody-drug conjugate that binds to CD138, which is overexpressed on multiple myeloma (MM) cells. Patients And Methods: We report from 2 clinical studies of...
7.
Welte T, Dellinger R, Ebelt H, Ferrer M, Opal S, Singer M, et al.
Intensive Care Med
. 2018 Apr;
44(4):438-448.
PMID: 29632995
Purpose: The CIGMA study investigated a novel human polyclonal antibody preparation (trimodulin) containing ~ 23% immunoglobulin (Ig) M, ~ 21% IgA, and ~ 56% IgG as add-on therapy for patients...
8.
van Vollenhoven R, Keystone E, Strand V, Pacheco-Tena C, Vencovsky J, Behrens F, et al.
Ann Rheum Dis
. 2018 Jan;
77(4):495-499.
PMID: 29343509
Objective: To evaluate the efficacy, biological activity and safety of tregalizumab in patients with active rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX). Methods: 321 patients were randomised...
9.
Hodkinson J, Bangs C, Wartenberg-Demand A, Bauhofer A, Langohr P, Buckland M, et al.
J Clin Immunol
. 2017 Apr;
37(4):332.
PMID: 28386703
No abstract available.
10.
Hodkinson J, Bangs C, Wartenberg-Demand A, Bauhofer A, Langohr P, Buckland M, et al.
J Clin Immunol
. 2017 Mar;
37(4):329-331.
PMID: 28293897
No abstract available.